[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
May 23/30, 2007

Improving Surveillance for Antimalarial Drug Resistance

Author Affiliations
 

Author Affiliations: US Department of Defense Global Emerging Infections Surveillance & Response System, Silver Spring, Md (Dr Chretien); Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand (Drs Fukuda and Noedl); and Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria (Dr Noedl).

JAMA. 2007;297(20):2278-2281. doi:10.1001/jama.297.20.2278

Global malaria control efforts depend increasingly on artemisinin derivatives because of resistance to other antimalarial drugs. Emergence of artemisinin resistance could be devastating for individuals with malaria, unless timely detection by surveillance systems allows evaluation of new treatments and interventions to counter the spread of resistance. However, instead of drug resistance monitoring, major sponsors of malaria control programs emphasize other essential antimalarial strategies far more strongly.

First Page Preview View Large
First page PDF preview
First page PDF preview
×